Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMPROvED

Financiado

Cerrado

IMPROvED IMproved Pregnancy Outcomes by Early Detection personalized medicine...

IMPROvED IMproved Pregnancy Outcomes by Early Detection personalized medicine for pregnant women novel metabolomic and proteomic biomarkers to detect pre eclampsia and improve outcome 1 in 20 first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequently, clinicians are unable to offer targeted surveillance or know... ver más

30/04/2018

UCC

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-04-30 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

UCC

0.00€ | Lider

METABOL

N.D. | Participante

RIJKSUNIVERSITEIT GRONINGEN

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PRECALI PREeclampsia risk stratification test development of a suit... 176K€ Cerrado

PID2020-115092GB-I00 DESARROLLO DE METODOS PROTEOMICA CUANTITATIVOS PARA APLICACI... 145K€ Cerrado

CTQ2009-07430 DESARROLLO DE PLATAFORMAS ANALITICAS EN METABOLOMICA PARA LA... 152K€ Cerrado

EQC2019-006485-P RENOVACIÓN PLATAFORMA IMAGEN MOLECULAR MS-IMAGING DE LA UNID... 592K€ Cerrado

IPOG Improving Pregnancy Outcomes Gloablly 3M€ Cerrado

EQC2018-005227-P Configuración de Plataforma de Proteómica cuantitativa de pr... 627K€ Cerrado

Líder del proyecto

UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto 1 in 20 first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequently, clinicians are unable to offer targeted surveillance or known/emerging preventative strategies. Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, especially in the field of mass spectrometry and the comprehensive mapping of the blood metabolome and proteome. The overall objective of the IMPROvED project is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia. This will involve a multicentre, phase IIa clinical study to assess and refine novel and innovative prototype tests based on emerging metabolomic and proteomic technologies developed by SMEs within the consortium. The study will i) recruit 5000 first time pregnant women; ii) establish a high calibre biobank, augmented by accurate clinical metadata; iii) determine whether prototype predictive assays and algorithms translate to the clinical environment; iv) assess potential synergy of a combined metabolomic and proteomic approach and v) progress regulatory approval and development of the selected test into the clinical arena. The application of new technologies to identify ‘at risk’ patients in early pregnancy will allow stratified care with personalized fetal and maternal surveillance, early diagnosis and timely intervention. If an effective test halved antenatal visits and administration of therapies (such as aspirin) to those at risk reduced the incidence of disease by only 20%, potential savings would approximate to €4 billion of the estimated €9 billion/yr spent in Europe providing antenatal care for nulliparous women and treatment for pre-eclampsia. Moreover, an accurate predictive test would be a crucial step in reducing the life-threatening complications of the disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores